OSSDSIGN Aktie

 

11 June 2025. Today, the annual general meeting of 2025 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (complete information and documents regarding the decisions of the meeting are available on the company's website www.ossdsign.com). The annual general meeting resolved:   -        to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2024;   -        that the company's result shall be carried forward in new account and that...

Uppsala, June 9, 2025. OssDsign AB (publ.) today announces, through the nomination committee, a revised proposal for election of the board of directors at the annual general meeting on June 11, 2025. In the notice convening the annual general meeting in OssDsign AB (publ) (the “Company”), to be held on 11 June 2025, the nomination committee proposed re-election of Simon Cartmell (also proposed to be re-elected as chairman), Christer Fåhraeus, Jill Schiaparelli and Newton Aguiar, and new-election of David Jern, as ordinary members of the board of directors.   The nomination committee...

STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding procedure that brought the company approximately SEK 158 million. In connection with the directed share issue, the company announced an updated strategy and revised its financial targets for the period 2025–2028....

June 3, 2025, 23:04 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) has completed a directed share issue of 11,500,000 shares at a subscription price of SEK 13.75 per share (the “Directed Issue”), through which the Company receives approximately SEK 158 million before deduction of transaction costs. The subscription price was determined based on an accelerated book-building procedure lead by DNB Carnegie Investment Bank AB (“DNB Carnegie”). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG,...

June 3, 2025, 19:35 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) earlier today informed that the Company has mandated DNB Carnegie Investment Bank AB (“DNB Carnegie”) to evaluate the conditions for carrying out a new share issue of approximately 9 million shares directed towards Swedish and international institutional investors (the “Directed Share Issue”). The interest in participating in the Directed Share Issue has been strong and OssDsign has therefore decided to investigate the conditions for increasing the scope to approximately 11.5 million shares. NOT FOR RELEASE,...

June 3, 2025, 17:31 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) intends to explore the conditions to carry out a directed share issue corresponding to approximately nine million shares through an accelerated bookbuilding procedure to Swedish and international institutional investors (the “Directed Issue”), starting immediately. OssDsign has engaged DNB Carnegie Investment Bank AB  (“DNB Carnegie”) to act as Sole Bookrunner in connection with the Directed Issue. In connection with the Directed Share issue, OssDsign announces an updated strategy, “ScaleToProfit”, together with...

Uppsala, May 14, 2025. Today, OssDsign AB (publ.) today announces that the company's share will be included in the MSCI Global Micro Cap Index, implemented as of the close of May 30, 2025. MSCI provides decision support and services to the global investment community and conducts quarterly updates of its equity indexes. In the latest revision, OssDsign has been included in the MSCI Global Micro Cap Index, implemented as of the close of May 30. Based on MSCI's expertise in research, data and technology, equity indexes of global shares are revised continuously to support clients' investment...

OssDsign AB (publ) announces that the Annual Report for 2024 is now available as a PDF on the company's website, www.ossdsign.com. A PDF version is also attached to this press release. “Despite operating in a highly competitive market, we have shown there are vast growth opportunities when offering state-of-the-art innovation that solves the clinical challenges” said Morten Henneveld, CEO, OssDsign AB.   For further information, please contact: Morten Henneveld, CEO, OssDsign AB Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com   Certified Adviser The Company's...

STOCKHOLM, SWEDEN, May 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has reached a new milestone with 10,000 patients treated with the innovative nanosynthetic bone graft OssDsign Catalyst on the US market....

The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 1:00 pm on Wednesday 11 June 2025 at Setterwalls Advokatbyrå's offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting. The board of directors has decided, pursuant to Chapter 7, Section 4, Paragraph 2 of the Swedish Companies Act and the company's articles of association, to apply the possibility of proxy collection in conjunction with the general meeting (se section Proxy collection below for more...

Uppsala, May 12, 2025. Today, OssDsign AB (publ.) announces that it has reached its milestone of 10,000 patients treated with the innovative nanosynthetic bone graft, OssDsign Catalyst, confirming its continued success in the U.S. orthobiologics market. The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021. ” With 10,000 patients treated, the adoption of OssDsign Catalyst is clearly accelerating. This is a substantial increase from the 5,000 patients reported in May...

Strong growth and best operating result ever OssDsign AB (publ) announces that the interim report for Q1 2025 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version is also attached to this press release.   The Q1 2025 results will also be presented at an investor webcast today May 6th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q1-2025/ or via the OssDsign website.     The first quarter in figures   · Net sales amounted to TSEK 44,493 (27,029), which translates to a growth...

STOCKHOLM, SWEDEN, April 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has notified a change of CEO during the second half of 2025. The purpose is to support the establishment of leadership with an even stronger presence and focus on the US market....

Uppsala, April 30, 2025. OssDsign® AB (publ.) today announces that Morten Henneveld will step down as CEO at the end of the year to support the establishment of leadership with an even stronger presence and focus on the US market. The board will begin the process of recruiting a new CEO to lead the company's continued expansion in the United States. Since the launch of OssDsign Catalyst in the U.S. in August 2021, and the following the strategic shift to become a pure play orthobiologics company, OssDsign has shown high double-digit growth. To lead the continued rapid growth and expansion in...

Uppsala, April 11, 2025. OssDsign® AB (publ.) today announces that a new preclinical study comparing the bone-forming potential of different silicate-containing calcium phosphate synthetic bone grafts has been published in the peer-reviewed scientific journal Journal of Orthopaedic Surgery and Research. The study demonstrates that OssDsign Catalyst® is the first clinically available synthetic bone graft to successfully generate robust, functional bone in challenging avascular environments at early time points. A research team led by Professor Iain R. Gibson from the University of Aberdeen...

Uppsala, April 9, 2025. OssDsign AB (publ.) today announces that the 24-month follow up results from the clinical study TOP FUSION will be published in the peer-reviewed journal, Biomedical Journal of Scientific & Technical Research. The results demonstrate a 100% spinal fusion rate and improved quality of life and pain after surgery with the innovative nanosynthetic bone graft OssDsign Catalyst. The data, soon to be published in the peer-reviewed journal, Biomedical Journal of Scientific & Technical Research, demonstrates that using OssDsign Catalyst leads to consistent and rapid bone...

Uppsala, February 25, 2025. OssDsign AB (publ.) today announced that the company has reached its target of 300 enrolled patients in the multi-center, prospective spinal fusion registry PROPEL. This registry, initiated in March 2022, collects real-world data from patients treated with OssDsign Catalyst. "When we initiated the PROPEL registry, we communicated a target of 300 patients. Reaching this milestone already confirms our capability to gather clinically relevant data and the successful enrollment is a direct result of surgeons' high interest in collaborating with OssDsign to evaluate...

Today, an extraordinary general meeting was held in OssDsign AB (publ). Below is a summary of the resolutions adopted at the extraordinary general meeting (in accordance with the proposals presented in the notice to attend the meeting kept available at the company's website www.ossdsign.com). The extraordinary general meeting resolved (i) to adopt the board's proposed resolution on a long-term incentive program for employees and contractors including a directed issue of warrants and approval of transfer of warrants; and (ii) to adopt the resolution proposed by certain shareholders regarding...

STOCKHOLM, SWEDEN, December 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests 4,6 million shares in the portfolio company OssDsign and thereby strengthens the investment company's liquidity. Karolinska Development holds nearly 5 million shares in OssDisgn after the divestment....

The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the extraordinary general meeting at 10:00 am on Wednesday 18 December 2024 at Setterwalls Advokatbyrå's offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting. The board of directors has decided, pursuant to Chapter 7, Section 4, Paragraph 2 of the Swedish Companies Act and the company's articles of association, to apply the possibility of proxy collection in conjunction with the general meeting (se section Proxy collection...